Is Big Pharma's Drug Research Finally Speeding Up?

http://www.forbes.com/sites/matthewherper/2012/12/14/moores-law-backward-is-drug-research-finally-speeding-up/ 

Industry analyst Jack Scannell, writing in Nature Reviews Drug Discovery, gave this economic quicksand a name: Eroom’s Law. That’s Moore’s Law backward.

There’s even a good example, from Pfizer’s Dolsten, of a drug that has come directly out of these changes. Xalkori originally failed. But researchers discovered that it was incredibly potent in 5% of patients with non-small cell lung cancer, giving Pfizer one of its most important new drugs in years. There have been some other drugs that were clearly the result of genomics that have succeeded, including many other targeted cancer medicines and Vertex’s cystic fibrosis drug, Kalydeco, but it’s still early to say that these new tools have led to better medicines.